A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Cancer Biol Ther · 2019 · PMC6343690 · PMID 30403909

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

not fully significantp = 0.06so close (0.05 < p ≤ 0.1)

As showed in Table 3 , not fully significant differences were observed when we analyzed objective responses according to ER/PgR status (p = 0.06).

also in 49 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.